AbbVie abandons late-stage lung cancer asset Rova-T - WTVB News

AbbVie abandons late-stage lung cancer asset Rova-T  WTVB News

(Reuters) - AbbVie Inc said on Thursday it will cease to develop its experimental drug Rova-T after the treatment failed to show survival benefit in a late-stage ...



Comments

Popular posts from this blog

Oncology: The disease, dynamics & challenges of market research

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Lung Cancer Among People Who Never Smoked